allergic rhinitis
Conditions
Interventions
control group:Yiqi Jiemin Decoction granules were simulated, one bag per time, orally administered twice a day for 14 consecutive days.
Low dose group:Granules made of 2/3 of the original prescription of Yiqi Jiemin Decoction, 1 bag per time, oral administration, twice a day, 14 consecutive days
High dose group:Granules made from the original dosage of Yiqi Jiemin Decoction, one bag per time, oral, twice a day, for 14 consecutive days
Sponsors
Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a. Age = 18, = 65; b. Clinical symptoms: two or more of the symptoms, such as itching, sneezing, water like nasal discharge, and nasal congestion, occur in the nose, and the symptoms persist or accumulate for more than 1 hour every day, even accompanied by eye itching, tears, conjunctival congestion and other eye symptoms; c. The severity of symptoms is assessed as moderate or severe, that is, the symptoms are severe or severe, which has a significant impact on the quality of life. The onset of symptoms is greater than 4d/week, and = 4 consecutive weeks d. Skin prick test and serum specific IgE positive are at least consistent with one of the two indicators e. Obtain the informed consent of the patient and be willing to participate in the experiment; f. The liver and kidney function of the patient is normal, so as to avoid the error caused by abnormal liver and kidney function damage after taking traditional Chinese medicine; g. The patient has a good mental status, and can objectively and accurately express their own symptoms and treatment effects.
Exclusion criteria
Exclusion criteria: a. The patient is in the acute attack period of asthma and cardiovascular and cerebrovascular diseases, or suffers from immunodeficiency disease, head and face trauma, tumor, or organ transplantation; b. Women in pregnancy or lactation; c. Patients who are using glucocorticoid (including oral and local external use) for more than one week; d. Those who receive other clinical trials within 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal Symptom Rating Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale;Nasal endoscopic nasal sign score;Rhinoconjunctivitis Daily Quality of Life Questionnaire; | — |
Countries
China
Contacts
Public ContactZhanfeng YAN
Outcome results
None listed